VIOXX was withdrawn from the world-wide market on September 30, 2004, following continuing reports that persons using VIOXX faced twice the risk of cardiovascular complications, including heart attack, stroke, and high blood pressure. 

Scientific studies suggested that a dose of 50 mg or more of VIOXX increased the risk of heart attack or stroke 3 times that of the general population.

Launched in Canada Vioxx was first approved for use in Canada in October 1999. By the year 2000, reports were surfacing linking Vioxx to an alarming series of associated various health complications, including cardiac and cardiovascular complications, liver damage, kidney damage, and lack of bone healing.

In 2003 IMS Health (an independent prescription tracking agency) reported that there were over 3.4 million prescriptions for VIOXX in Canada last year, making it the 10th most prescribed drug in the country. It is estimated that over 700,000 Canadians have taken the drug to alleviate arthritis and severe menstrual pain.  

Merck is the world’s third largest drug maker. VIOXX accounted for some $2.5 billion in sales in 2003. More than 2 million people take VIOXX world-wide. This is thought to be the largest voluntary drug recall in history.  

This site has been developed in order to provide the public with information regarding Vioxx, the side effects and new developments in the lawsuits filed around the world.

For further information regarding your legal rights and the withdrawal of Vioxx, contact Rochon Genova LLP at 1-866-881-2292.